Neuro Partnerships Position Exicure as a licensing or co-development partner around Nav1.7 non-opioid pain and other CNS targets to pharma companies seeking non-addictive analgesics and CNS therapies. Highlight the platform’s ability to screen thousands of oligonucleotides and validate top candidates in cell and animal models to de-risk early-stage assets.

Discovery Services Offer in-house high-throughput nucleic acid synthesis and screening as a discovery service for biotech firms needing rapid oligonucleotide optimization and target validation. Emphasize the dedicated 30,000 square foot facility and proven in vitro and in vivo CNS performance to shorten development timelines.

Funding Opportunities The Nasdaq equity notices and late Form 10-Q filings suggest a funding-sensitive window for strategic investors, milestone-based licenses, or other capital-efficient deals to advance core CNS programs. Target biotech investors, strategic industry partners, and grant programs interested in early-stage oligonucleotide therapies.

Asia Collaboration Leverage the existing Adbiotech collaboration in Korea to explore additional Asia-focused partnerships for Burixafor-based combos and other CNS assets across multiple therapeutic areas. Use this as a model to approach regional pharma and CROs seeking co-development opportunities and access to Exicure’s discovery platform.

Portfolio Expansion With a lead Nav1.7 program and several CNS candidates, there is clear portfolio value for licensing or collaboration deals across pain and neurodegenerative disorders. Develop targeted outreach to companies focused on neurological pain, Huntington’s disease, Angelman syndrome, Batten disease, spinocerebellar ataxia, and ALS to monetize the pipeline.